An animal model for cidofovir (HPMPC) toxicity: Intraocular pressure and histopathologic effects

Experimental Eye Research

Volumn 64, Issue 5, 1997, Pages 795-806

  Taskintuna, I ^a   Banker, A S ^a   Rao, N A ^b   Wiley, C A ^c   Flores Aguilar, M ^a   Munguia, D ^a   Bergeron Lynn, G ^a   De Clercq, E ^d   Keefe, K ^e   Freeman, W R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

AIDS; Antiviral drugs; Cidofovir (HPMPC); Drug delivery

Indexed keywords

CIDOFOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CILIARY BODY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; EPITHELIUM CELL; GUINEA PIG; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINITIS;

EID: 0031149309     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1006/exer.1996.0273     Document Type: Article

References (49)

1. Anand, R., Nightingale, S. D., Fish, R. H., Smith, T. J. and Ashton, P. (1993). Control of CMV retinitis using sustained release of intraocular ganciclovir. Arch. Ophthalmol. 111, 223-7.
2. Banker, A. S., Arévalo, J. F., Rahhal, F. M., Ishimoto, B., Munguia, D., Berry, C., De Clercq, E., Ochabski, R., Taskintuna, I. and Freeman W. R. Intraocular pressure and aqueous humor dynamics in AIDS patients treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am. J. Ophthalmol. In Press.
3. Besen, G., Flores-Aguilar and M., Kerry, K. A. (1995). Long-term therapy of herpes retinitis in an animal model with high-concentrated liposome-encapsulated (HPMPC). Arch. Ophthalmol. 113, 661-8.
4. Bischofberger, N., Hitchcock, M. J. M. and Chen, M. S. (1994). 1-[((S )-2-Hydroxy-2-oxo-1,4,2 -dioxaphosphorinan-5-yl)Methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob. Agents Chemother. 38, 2387-91.
5. Cantrill, H. L., Henry, K., Melroe, H., Knobloch, W. H., Ramsay, R. C. and Balfour, H. H. Jr. (1989). Treatment of CMV retinitis with intravetreal ganciclovir: long term results. Ophthalmology 96, 367-74.
6. Cochereau-Massin, I., Le Hoang, P. and Lautier-Frau, M. (1991). Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 98, 1348-55.
7. Daikos, G. L., Pulido, J., Kathpalia, S. B. and Jackson, G. G. (1988). Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression. Br. J. Ophthalmol. 72, 521-4.
8. De Clercq, E., Holy, A., Rosenberg, I., Sakuma, T., Balzarini, J. and Maugdal, P. C. (1986). A novel selective broad-spectrum anti-DNA virus agent. Nature (London) 323, 464-7.
9. De Clercq, E., Sakuma, T. and Baba, M. (1987). Antiviral activity of phosphonyl-methoxyalkyl derivatives of purine and pyrimidines. Antiviral. Res. 8, 261-72.
10. Diaz-Llopis, M., Chipont, E., Sanchez, S., Espana, E., Navea, A. and Menezo, J. L. (1992). Intravitreal foscarnet for CMV retinitis in a patient with AIDS. Am. J. Ophthalmol. 114, 742-7.
11. Dolnak, D. R., Munguia, D., Wiley, C. A., De Clerq, E., Bergeron-Lynn, G. L., Boscher, C., Connor, J. D., Sherwood, C., Capparelli, E., Amani, R. and Freeman, W. R. (1992). Lack of retinal toxicity of the anti-cmv drug (S)-1-(3-hydroxy-2-phosphonyl methoxypropyl) cytosine (HPMPC). Invest. Ophthalmol. Vis. Sci. 33, 1557-63.
12. Drew, W. L., Ives, D. and Lalezari, J. P. (1995). Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex cooperative oral ganciclovir study group. New Eng. J. of Med. 333, 615-20.
13. Fanning, M. M., Read, S. E. and Benson, M. (1990). Foscarnet therapy of CMV retinitis in AIDS. J. Acquir. Immune Defic. Syndr. 3, 472-9.
14. Flores-Aguilar, M., Kuppermann, B. D., Quiceno, J. I., Dankner, W. M., Wolf, D. G., Caparelli, E. V., Connor, J. D., Sherwood, C. H., Fullerton, S., Gambertoglio, J. G., Spector, S. A. and Freeman, W. R. (1993). Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Ophthalmology 100, 1022-31.
15. Flores-Aguilar, M., Huang, J. S., Wiley, C. A., De Clercq, E., Vuong, C., Bergeron-Lynn, G., Chandler, B., Munguia, D. and Freeman, W. R. (1994). Long acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC). J. Infect. Dis. 169, 642-7.
16. Freeman, W. R. (1989). Intraocular antiviral therapy. Arch. Ophthalmol. 107, 1737-9.
17. Hammond, B. R. and Bhattaacherjee, P. (1984). Calibration of the Alcon applanation pneumatonograph and Perkins tonometer for use in rabbits and cats. Curr. Eye Res. 3, 1155-8.
18. Heinemann, M. H. (1989). Long term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch. Ophthalmol. 107, 1767-72.
19. Henry, K., Cantrill, H., Fletcher, C., Chinnock, B. J. and Balfour, H. H. Jr. (1987). Use of intravitreal ganciclovir (Dihydroxy propoxymetil guanine) for cytomegalovirus retinitis in a patient with AIDS. Am. J. Ophthalmol. 103, 17-23.
20. Hitchcock, M. J. M., Lacy, S. A., Lindsey, J. R. and Kern, E. R. (1995). The cyclic congener of cidofovir has reduced nephrotoxicity in three species. Antiviral Res. 26, A358.
21. Holland, G. N., Buhles, W. C. Jr. and Mastre, B. (1989). A controlled prospective study of ganciclovir treatment for cytomegalovirus retinopathy: use of a standardized system for the assessment of disease outcome. Arch. Ophthalmol. 107, 1759-66.
22. Hoover, D. R., Peng, Y. and Saah, A. (1996). Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch. Ophthalmol. 114, 821-7.
23. Jabs, D. A., Enger, C. and Bartlett, J. G. (1989). CMV retinitis and acquired immunodeficiency syndrome. Arch. Ophthalmol. 107, 75-80.
24. Jacobson, M. A., Causey, D. and Polsky, B. (1993). A dose ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J. Infect. Dis. 168, 444-8.
25. Kirsch, L. S., Arevalo, J. F. and De Clercq, E. (1995a). Phase I/II study of intravitreal cidofovir for the treatment of CMV retinitis in patients with AIDS. Am. J. Ophthalmol. 119, 466-76.
26. Kirsch, L. S., Arevalo, J. F., Chavez de La Paz, E., Munguia, D., De Clercq, E. and Freeman, W. R. (1995b). Intravitreal Cidofovir (HPMPC) Treatment of CMV retinitis in patients with AIDS. Ophthalmology 102, 533-42.
27. Kuppermann, B. D., Assil, K. K., Vuong, C. (1996). Liposome-encapsulated (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl) Cytosine for long-acting therapy of viral retinitis. J. Infect. Dis. 173, 18-23.
28. Lalezari, J. P., Drew, W. L. and Glutzer, E. (1995). (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): Results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171, 788-96.
29. Martin, D. F., Parks, D. J. and Mellow, S D. (1994). Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch. Ophthalmol. 112, 1531-9.
30. Maurice, D.M. (1987). Use of intravitreal ganciclovir (Dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am. J. Ophthalmol. 103, 842-3.
31. Mermoud, A., Baerveldt, G. and Minckler, D. S. (1994). Intraocular pressure in rats. Invest. Ophthalmol. Vis. Sci. 35, 2455-60.
32. Neyts, J., Snoeck, R. and Schols, D. (1990). Selective inhibition of human CMV DNA synthesis by (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-Dihydroxy-2-propoxymethyl)-Guanine (DHPG). Virology 179, 41-50.
33. Palestine, A. G., Stevens, G. Jr. and Lane, H. C. (1986). Treatment of CMV retinitis with Dihydroxy-Propoxymethyl) Guanine. Am. J. Ophthalmol. 101, 95-101.
34. Palestine, A. G., Polis, M. A. and De Smet, M. D. (1991). A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. 115, 665-73.
35. Polis, M. A., Spooner, K. M. and Baird, B. F. (1995). Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Chemother. 39, 882-6.
36. Priehs, D. R., Gum, C.G. and Whitley, R. D. (1990). Evaluation of three applanation tonometers in dogs. Am. J. Vet. Res. 51, 1547-50.
37. Rahhal, F. M., Arévalo, J. F., Munguia, D., Taskintuna, I., Chavez de la Paz, E., Azen, S. and Freeman, W. R. (1996). Intravitreal cidofovir (HPMPC) for the maintenance of cytomegalovirus retinitis. Ophthalmology 103, 1078-83.
38. Rahhal, F. M., Arévalo, J. F., Munguia, D., Taskintuna, I., Chavez de la Paz, E., Azen, S. P. and Freeman, W. R. (1996). Treatment and maintenance of CMV retinitis with intravitreal cidofovir (HPMPC) in patients with AIDS. Ann. Intern. Med. 125, 98-103.
39. Sanborn, G. E., Anand, R. and Torti, R. R. (1992). Sustained-release ganciclovir therapy for treatment of CMV retinitis; use of an intravitreal device. Arch Ophthalmol. 110, 188-95.
40. Snoeck, R., Sakuma, T., De Clercq, E., Rosenberg, I. and Holy, A. (1988). (S)-9-(3-Hydroxy-2-phosphonylmethoxypropyl) cytosine, A potent and selective inhibitor of human CMV replication. Antimicrob. Chemother. 32, 1839-44.
41. Spector, S. A., Weingeist, T. and Pollard, R. B. (1993). A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J. Infect. Dis. 168, 557-63.
42. Spector, S. A., McKinley, G. F. and Lalezari, J. P. (1996). Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N. Eng. J. Med. 334, 1491-7.
43. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. (1992). Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N. Eng. J. Med. 326, 213-20.
44. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trial Group. (1994). Foscarnet-Canciclovir Cytomegalovirus Retinitis Trial 4. Ophthalmology 101, 1250-61.
45. Taskintuna, I., Rahhal, F. M., Arévalo, J. F., Munguia, D., Banker, A. S., De Clercq, E. and Freeman, W. R. (1997). Low dose intravitreal HPMPC (cidofovir) therapy of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Ophthalmology. In Press.
46. Ussery, F. M. 3d, Gibson, S. R., Conklin, R. H., Piot, D. F., Stool, E. W. and Conklin, A. J. (1988). Intravitreal ganciclovir in the treatment of AIDS-associated CMV retinitis. Ophthalmology 95, 640-8.
47. Verheyden, J. P. H. (1988). Evolution of Therapy for CMV infection. Rev. Infect. Dis. 10 (Suppl. 3), S477-89.
48. Votruba, I., Bernaerts, R. and Sakuma, T. (1987). Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-Hydroxy-2-phosphonylmethoxypropyl) adenine and inhibition of viral DNA synthesis. Mol. Pharmacol. 32, 524-9.
49. Walker, R. E., Litovitz, T. L. and Langham, M. E. (1972). Pneumatic applanation tonometer studies: II: Rabbit cornea data. Exp. Eye Res. 13, 187-93.